2010 News

• 12.13.2010
  Press Release IR News

  Santen Launches DIQUAS Ophthalmic Solution 3% for Dry Eye Treatment in Japan

• 11.02.2010
  Press Release IR News

  Santen Announces Financial Result for the Second Quarter ended September 30, 2010

• 09.28.2010
  Press Release IR News

  Reorganization of manufacturing function and transfer of Osaka plant

• 08.03.2010
  Press Release IR News

  Santen Announces Financial Result for the First Quarter ended June 30, 2010

• 07.06.2010
  Press Release IR News

  Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)

• 06.23.2010
  Press Release IR News

  Notice on the Allotment of Stock Options (Stock Acquisition Rights)

• 06.11.2010
  Press Release IR News

  Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug

• 05.11.2010
  Press Release IR News

  Santen Announces Financial Results for the Year ended March 31, 2009

• 05.11.2010
  Press Release IR News

  Renewal of the Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)

• 05.11.2010
  Press Release IR News

  Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors

• 05.11.2010
  Press Release IR News

  Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers

• 05.11.2010
  Press Release IR News

  Notice of the Change of Representative Director and the Nominations for the Members of the Board of Directors

• 05.06.2010
  Press Release IR News

  Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN® in Korea

• 05.03.2010
  Press Release IR News

  Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments

• 04.16.2010
  Press Release IR News

  Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan

• 04.16.2010
  Press Release IR News

  MHLW Grants Approval for COSOPT Combination Ophthalmic Solution

• 03.10.2010
  Press Release IR News

  Notice of the appointment of Corporate Officers

• 03.10.2010
  Press Release IR News

  Change of management positions at Santen Inc.

• 03.02.2010
  Press Release IR News

  Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension

• 03.02.2010
  Press Release IR News

  Santen Files Manufacturing/Marketing Approval of its Broad Spectrum Anti-Infective Ophthalmic Solution DE-108 (Generic name: Levofloxacin, high concentration)

• 02.02.2010
  Press Release IR News

  Santen Announces Financial Result for the Third Quarter ended December 31, 2009

News Archive